Source: EURLEX
Language: en
Format: md

|  |  |  |
| --- | --- | --- |
| European flag | Official Journal  of the European Union | EN  Series C |

---

|  |  |  |
| --- | --- | --- |
|  | C/2023/599 | 31.10.2023 |

Prior notification of a concentration

(Case M.11043 – NOVOZYMES / CHR HANSEN HOLDING)

(Text with EEA relevance)

(C/2023/599)

1.

On 20 October 2023, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_202300599EN.000101-E0001).

This notification concerns the following undertakings:

|  |  |
| --- | --- |
| — | Novozymes A/S (‘NZ’, Denmark), a publicly listed company solely controlled by Novo Holdings A/S, |

|  |  |
| --- | --- |
| — | Chr. Hansen Holding A/S (‘CH’, Denmark), a publicly listed company with no controlling shareholder. |

NZ will enter into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation with CH.

The concentration is accomplished by way of purchase of securities.

2.

The business activities of the undertakings concerned are the following:

|  |  |
| --- | --- |
| — | NZ is a global bioscience company and is predominantly a developer, manufacturer and supplier of industrial enzymes to be used within household care, bioenergy, grain & tech processing, agriculture and animal health & nutrition, and food & beverage and, to a lesser extent, a manufacturer of probiotics for human and animal health and biologicals for plant health, |

|  |  |
| --- | --- |
| — | CH is a global differentiated bioscience company that develops natural ingredients solutions for the food, nutritional, pharmaceutical and agricultural industries for a variety of foods, beverages, dietary supplements, animal feed and crop protection. The Chr. Hansen Group is predominantly a manufacturer and supplier of cultures for food & beverage, but, to a lesser extent, also manufactures probiotics for human and animal health, biologicals for plant health and enzymes. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.11043 – NOVOZYMES / CHR HANSEN HOLDING

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

|  |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

---

ELI: http://data.europa.eu/eli/C/2023/599/oj

ISSN 1977-091X (electronic edition)

---

[Top](#document1)